圆锥角膜遗传变异的全基因组关联研究
该研究在澳大利亚、美国和北爱尔兰的眼科诊所开展全基因组关联研究,发现队列包括522例患者和655名对照, replication队列包括818例患者和3858名对照。研究鉴定出PNPLA2和CSNK1E两个新位点达到全基因组显著性,其中PNPLA2位点在全部4个队列分析中仍显著。
要点
- 发现PNPLA2和CSNK1E两个与圆锥角膜达到全基因组显著性的新位点。
- PNPLA2位点在全部4个队列合并分析中仍达全基因组显著性(P=2.45×10-8)。
- MAML2位点仅达P<1.00×10-6的提示性关联(P=3.91×10-7)。
核心结论
- 在相对较大的圆锥角膜全基因组关联研究中,发现11号染色体PNPLA2区域存在全基因组显著位点。
研究设计与样本
- 研究数据来自澳大利亚、美国和北爱尔兰的眼科诊所,时间范围为2006年1月至2019年3月。
- 发现队列为澳大利亚的522例圆锥角膜患者和655名对照,使用Illumina HumanCoreExome芯片基因分型。
- 对P<1.00×10-6的单核苷酸多态性在3个额外队列中进行验证,验证队列共818例患者和3858名对照。
主要发现
- 发现队列中,11号染色体PNPLA2基因rs61876744达到全基因组显著性(P=7.46×10-9)。
- 发现队列中,22号染色体CSNK1E基因上游2.2 kb的rs138380达到全基因组显著性(P=6.35×10-12)。
- 11号染色体MAML2基因位点P=3.91×10-7,未达全基因组显著性。
- PNPLA2位点在全部4个队列合并分析中达到全基因组显著性(P=2.45×10-8)。
关键数值与推荐
- 全基因组显著性阈值定义为P<5.00×10-8。
- 发现阶段采用P<1.00×10-6作为进入验证分析的标准。
- 关联分析使用logistic回归,校正前3个主成分以调整 ancestry。
临床怎么用
- PNPLA2和CSNK1E位点的发现为圆锥角膜的遗传易感性提供了新证据。
- 这些位点目前尚不能直接用于临床基因检测或风险预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Keratoconus is a condition in which the cornea progressively thins and protrudes in a conical shape, severely affecting refraction and vision. It is a major indication for corneal transplant. To discover new genetic loci associated with keratoconus and better understand the causative mechanism of this disease, we performed a genome-wide association study on patients with keratoconus. OBJECTIVE: To identify genetic susceptibility regions for keratoconus in the human genome. DESIGN, SETTING, AND PARTICIPANTS: This study was conducted with data from eye clinics in Australia, the United States, and Northern Ireland. The discovery cohort of individuals with keratoconus and control participants from Australia was genotyped using the Illumina HumanCoreExome single-nucleotide polymorphism array. After quality control and data cleaning, genotypes were imputed against the 1000 Genomes Project reference panel (phase III; version 5), and association analyses were completed using PLINK version 1.90. Single-nucleotide polymorphisms with P < 1.00 × 10-6 were assessed for replication in 3 additional cohorts. Control participants were drawn from the cohorts of the Blue Mountains Eye Study and a previous study of glaucoma. Replication cohorts were from a previous keratoconus genome-wide association study data set from the United States, a cohort of affected and control participants from Australia and Northern Ireland, and a case-control cohort from Victoria, Australia. Data were collected from January 2006 to March 2019. MAIN OUTCOMES AND MEASURES: Associations between keratoconus and 6 252 612 genetic variants were estimated using logistic regression after adjusting for ancestry using the first 3 principal components. RESULTS: The discovery cohort included 522 affected individuals and 655 control participants, while the replication cohorts included 818 affected individuals (222 from the United States, 331 from Australia and Northern Ireland, and 265 from Victoria, Australia) and 3858 control participants (2927 from the United States, 229 from Australia and Northern Ireland, and 702 from Victoria, Australia). Two novel loci reached genome-wide significance (defined as P < 5.00 × 10-8), with a P value of 7.46 × 10-9 at rs61876744 in patatin-like phospholipase domain-containing 2 gene (PNPLA2) on chromosome 11 and a P value of 6.35 × 10-12 at rs138380, 2.2 kb upstream of casein kinase I isoform epsilon gene (CSNK1E) on chromosome 22. One additional locus was identified with a P value less than 1.00 × 10-6 in mastermind-like transcriptional coactivator 2 (MAML2) on chromosome 11 (P = 3.91 × 10-7). The novel locus in PNPLA2 reached genome-wide significance in an analysis of all 4 cohorts (P = 2.45 × 10-8). CONCLUSIONS AND RELEVANCE: In this relatively large keratoconus genome-wide association study, we identified a genome-wide significant locus for keratoconus in the region of PNPLA2 on chromosome 11.
引用
- McComish BJ, Sahebjada S, Bykhovskaya Y, et al. Association of Genetic Variation With Keratoconus. JAMA Ophthalmol. 2020. PMID: 31855235. doi:10.1001/jamaophthalmol.2019.5293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。